Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade.

Journal of immunology (Baltimore, Md. : 1950) - 1 Dec 2005

Maker Ajay V, Attia Peter, Rosenberg Steven A

Abstract excerpt

We have demonstrated previously that the administration of CTLA-4 blockade has mediated objective cancer regression and autoimmunity in patients with metastatic melanoma. To explore the mechanism of these in vivo effects, we have studied the changes in lymphocyte phenotype and function in patient...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Differentiation
Share to Autoimmunity
Share to CD4 Antigens

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CD8 Antigens

Share to CTLA-4 Antigen

Share to Forkhead Transcription Factors

Share to Kidney Neoplasms

Share to Receptors, Interleukin-2

Source

Open in PubMed Open full text

Identifiers

PMID: 16301685
DOI: 10.4049/jimmunol.175.11.7746
PMCID: PMC1473972

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-16301685-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade.PMID 16301685Read ↗

Markers for anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) therapy in melanoma.Semantic proximity Read ↗

Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response.Semantic proximity Read ↗

CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashionSemantic proximity Read ↗

Differential CTLA-4 expression in human CD4+ versus CD8+ T cells is associated with increased NFAT1 and inhibition of CD4+ proliferationSemantic proximity Read ↗

Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade.Semantic proximity Read ↗

Tumor evasion may occur via expression of regulatory molecules: a case for CTLA-4 in melanoma.Semantic proximity Read ↗

Characterization and augmentation of CD4+ cytotoxic T cell lines against melanoma.Semantic proximity Read ↗

CTLA-4 blockade boosts the expansion of tumor-reactive CD8+ tumor-infiltrating lymphocytes in ovarian cancer.Semantic proximity Read ↗

Clinical and immunological studies in advanced cancer patients sequentially treated with anti CD3 monoclonal antibody (OKT3) and interleukin-2.Semantic proximity Read ↗

A Transendocytosis Model of CTLA-4 Function Predicts Its Suppressive Behavior on Regulatory T CellsSemantic proximity Read ↗

Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells.Semantic proximity Read ↗

Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.